[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO2021000447A2 - Inhibidores de proteína tirosina fosfatasa y sus métodos de uso - Google Patents

Inhibidores de proteína tirosina fosfatasa y sus métodos de uso

Info

Publication number
CO2021000447A2
CO2021000447A2 CONC2021/0000447A CO2021000447A CO2021000447A2 CO 2021000447 A2 CO2021000447 A2 CO 2021000447A2 CO 2021000447 A CO2021000447 A CO 2021000447A CO 2021000447 A2 CO2021000447 A2 CO 2021000447A2
Authority
CO
Colombia
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
phosphatase inhibitors
ptpn1
Prior art date
Application number
CONC2021/0000447A
Other languages
English (en)
Inventor
Elliot Farney
Roohollah Kazem Shiroodi
Zhaoming Xiong
Qingwei I Zhang
Matthew O'connor
Geoff Halvorsen
Hongyu Zhao
Christina Baumgartner
Jennifer M Frost
Phil Kym
Jason R Abbott
Andrew Bogdan
Christos Economou
Xueqing Wang
Original Assignee
Abbvie Inc
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Calico Life Sciences Llc filed Critical Abbvie Inc
Publication of CO2021000447A2 publication Critical patent/CO2021000447A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos útiles para inhibir proteína tirosina fosfatasa, por ejemplo, proteína tirosina fosfatasa no receptora de tipo 2 (PTPN2) y/o proteína tirosina fosfatasa no receptora de tipo 1 (PTPN1) y para tratar enfermedades, trastornos y condiciones relacionadas que responden favorablemente al tratamiento con inhibidor de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
CONC2021/0000447A 2018-06-21 2021-01-19 Inhibidores de proteína tirosina fosfatasa y sus métodos de uso CO2021000447A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688226P 2018-06-21 2018-06-21
PCT/US2019/038459 WO2019246513A1 (en) 2018-06-21 2019-06-21 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2021000447A2 true CO2021000447A2 (es) 2021-07-19

Family

ID=67254011

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0000447A CO2021000447A2 (es) 2018-06-21 2021-01-19 Inhibidores de proteína tirosina fosfatasa y sus métodos de uso

Country Status (23)

Country Link
US (1) US10954202B2 (es)
EP (1) EP3810580A1 (es)
JP (2) JP7217762B2 (es)
KR (2) KR20230074286A (es)
CN (1) CN112955438A (es)
AR (1) AR125425A1 (es)
AU (2) AU2019290197B2 (es)
BR (1) BR112020026086A2 (es)
CA (1) CA3104507A1 (es)
CL (1) CL2020003316A1 (es)
CO (1) CO2021000447A2 (es)
CR (1) CR20210017A (es)
DO (1) DOP2020000252A (es)
EC (1) ECSP21003520A (es)
IL (1) IL279587A (es)
MA (1) MA52963A (es)
MX (2) MX2020014223A (es)
PE (1) PE20210372A1 (es)
PH (1) PH12020552228A1 (es)
SG (1) SG11202012820PA (es)
TW (1) TW202016082A (es)
UY (1) UY38272A (es)
WO (1) WO2019246513A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
MX2024010859A (es) * 2019-03-14 2024-09-11 Calico Life Sciences Llc Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
AU2020395612A1 (en) * 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
JP2023507774A (ja) * 2019-12-18 2023-02-27 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
EP4359409A1 (en) * 2021-06-21 2024-05-01 Calico Life Sciences LLC Degrader compounds and uses thereof
CN118525016A (zh) * 2021-11-11 2024-08-20 卡里科生命科学有限责任公司 蛋白酪氨酸磷酸酶抑制剂及其使用方法
AU2022386164A1 (en) * 2021-11-11 2024-05-23 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024102791A1 (en) * 2022-11-09 2024-05-16 Bristol-Myers Squibb Company Indazol substituted 1,2,5-thiadiazolidin derivatives as inhibitors of protein tyrosine phosphatase (ptpn2) for the treatment of cancer diseases
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
IL161582A0 (en) 2001-10-30 2004-09-27 Applied Research Systems Use of oxindole hydrazide derivatives for the preparation of pharmaceutical compositions, certain such new derivatives and their preparation
IL164262A0 (en) * 2002-04-03 2005-12-18 Novartis Ag 5-Substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as ptpase 1b inhibitors
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2008142198A2 (en) 2007-05-23 2008-11-27 Valtion Teknillinen Tutkimuskeskus A method for inhibiting or stimulating angiogenesis in an individual
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
WO2010118241A2 (en) 2009-04-08 2010-10-14 Indiana University Research & Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
EP2531616A4 (en) 2010-02-03 2013-07-10 Univ Monash DIAGNOSTIC AND PROGNOSIS ASSAY FOR BREAST CANCER
CN106471004A (zh) 2014-02-28 2017-03-01 麦吉尔大学学术发展皇家学院 作为用于免疫疗法的apc活化剂的tc‑ptp抑制剂
AU2015274242A1 (en) 2014-06-10 2016-12-22 Monash University Method of producing leukocytes using PTPN2 inhibition for adoptive cell transfer
KR101826690B1 (ko) 2015-11-06 2018-03-22 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
US11273166B2 (en) 2017-06-13 2022-03-15 Monash University Methods and compositions for the treatment of obesity
CA3073755A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill Universit Enhancing cd8+ t cells for adoptive cell therapy by inhibiting ptpn1 (ptp1b) and ptpn2 (tc-ptp)

Also Published As

Publication number Publication date
CR20210017A (es) 2021-11-03
MX2020014223A (es) 2021-06-23
KR102533477B1 (ko) 2023-05-18
MX2024004318A (es) 2024-04-23
JP2021530443A (ja) 2021-11-11
PH12020552228A1 (en) 2021-08-16
TW202016082A (zh) 2020-05-01
ECSP21003520A (es) 2021-02-26
CL2020003316A1 (es) 2021-06-11
EP3810580A1 (en) 2021-04-28
PE20210372A1 (es) 2021-02-26
AR125425A1 (es) 2023-07-19
US10954202B2 (en) 2021-03-23
CN112955438A (zh) 2021-06-11
KR20210034589A (ko) 2021-03-30
AU2019290197B2 (en) 2023-08-24
KR20230074286A (ko) 2023-05-26
BR112020026086A2 (pt) 2021-03-23
IL279587A (en) 2021-03-01
JP2023055771A (ja) 2023-04-18
UY38272A (es) 2019-12-31
WO2019246513A1 (en) 2019-12-26
SG11202012820PA (en) 2021-01-28
US20210009542A1 (en) 2021-01-14
MA52963A (fr) 2021-04-28
AU2019290197A1 (en) 2021-01-21
DOP2020000252A (es) 2021-07-15
AU2023263567A1 (en) 2023-11-30
JP7217762B2 (ja) 2023-02-03
CA3104507A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
MX2020004534A (es) Moduladores de la vía integrada del estrés.
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
EA201691135A1 (ru) Новые ингибиторы глутаминазы
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
ECSP20082339A (es) Moduladores de la expresión de apol1
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112022010672A2 (pt) Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica
ECSP21042779A (es) Moduladores de la expresión de irf5
EA201991267A1 (ru) Ингибиторы мутантных изоцитратдегидрогеназ и их композиции и способы